Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

colorectacl cancer

- PMLiVE

FDA fast-tracks Bayer’s prostate cancer radiotherapy

Priority review for radium-223 dichloride, formerly called Alpharadin

e-Therapeutics raises £40m to support oncology pipeline

Will fund development of ETS2101 for brain cancer and other potential indications

- PMLiVE

Bayer submits oral PAH drug riociguat for approval

Set to challenge Actelion and Gilead

Just Health PR wins Caris Life Sciences brief

Bioscience company to launches its tumour profiling technology in Europe

- PMLiVE

Celgene gets US green light for blockbuster candidate Pomalyst

FDA approval to treat multiple myeloma

- PMLiVE

FDA proffers guidance for new Alzheimer’s drugs

Encourages approach that tackles disease in its early stages

- PMLiVE

Sanofi receives EU approvals for diabetes and cancer drugs

Zaltrap and Lyxumia granted marketing authorisation by European Commission

- PMLiVE

FDA says approval of generic Doxil will ease cancer drug shortage

Allows Sun Pharma to manufacture its own version of the medicine

FDA clears Hyperion’s Ravicti for urea cycle disorders

Plans to launch in US by end of April

- PMLiVE

NICE turns down diabetes and ovarian cancer drugs for NHS use

Disappointment for BMS/AZ’s Forxiga and Roche’s Avastin

- PMLiVE

FDA advisors back Boehringer’s COPD drug olodaterol

Committee votes 15 to 1 in favour despite cancer concerns

Roche - Basel

Roche delivers solid sales gain in 2012

New cancer products, such as Perjeta and Zelboraf, help growth

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links